Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

CDK2-IN-55

  Cat. No.:  DC80401  
Chemical Structure
3093350-55-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
CDK2-IN-55 (Compound 12c) is a CDK2 inhibitor with an IC50 value of 4.7 nM. CDK2-IN-55 also has a strong inhibitory effect on CDK1 (IC50 = 26.3 nM), moderate inhibitory effects on Aurora A (IC50 = 92.0 nM) and CDK9 (IC50 = 288 nM), and very weak inhibitory activities on CDK4, CDK6, DYRK1A, and GSK3β (IC50 > 1000 nM). CDK2-IN-55 shows strong anti-proliferative activity against various cancer cell lines, inducing cell cycle arrest and apoptosis. CDK2-IN-55 can be used for research on colorectal cancer, lung cancer, and cervical cancer.
Cas No.: 3093350-55-8
Chemical Name: CDK2-IN-55
Formula: C19H23FN4O4S
M.Wt: 422.47
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Cat. No. Product name Field of application
DC81110 N6-Hydroxynorvalylcarbamoyladenosine N6-Hydroxynorvalylcarbamoyladenosine (hn6A) (compound 1) is a nucleoside discovered in unfractionated tRNA from Thermodesulfobacterium commune. N6-Hydroxynorvalylcarbamoyladenosine is a modified nucleoside.
DC80069 3'-O-(2-Nitrobenzyl)-dTTP 3'-O-(2-Nitrobenzyl)-dTTP acts as a reversible terminator for DNA chain elongation. 3'-O-(2-Nitrobenzyl)-dTTP interacts with 9°N polymerase (exo-) A485L/Y409V, gets recognized and incorporated into the elongating DNA chain, thereby temporarily terminating the polymerase reaction. 3'-O-(2-Nitrobenzyl)-dTTP carries a 3'-O-(2-nitrobenzyl) blocking group, which can be removed by laser irradiation to regenerate the free 3'-OH− group and restore polymerase activity. 3'-O-(2-Nitrobenzyl)-dTTP is applicable in DNA sequencing studies.
DC80066 3'-O-(2-Nitrobenzyl)-dATP 3'-O-(2-Nitrobenzyl)-dATP is a reversible and photolabile DNA synthesis terminator. 3'-O-(2-Nitrobenzyl)-dATP incorporates into growing DNA strands to terminate synthesis in a base-specific manner. 3'-O-(2-Nitrobenzyl)-dATP undergoes efficient photolytic removal of its 3'-protecting group upon UV exposure to enable reinitiation of DNA synthesis. 3'-O-(2-Nitrobenzyl)-dATP supports development of the Base Addition Sequencing Scheme (BASS) via a complete stop-start DNA synthesis cycle.
DC80060 3-Chloropropan-1-amine hydrochloride 3-Chloropropan-1-amine hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.
DC80050 3-(4-Bromophenyl)propanoic acid 3-(4-Bromophenyl)propanoic acid is a PROTAC linker that can be used in the synthesis of PROTACs.
DC80036 2-Bromo-LSD D-Tartrate 2-Bromo-LSD D-Tartrate is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist. 2-Bromo-LSD D-Tartrate acts as both a potent partial agonist (with an EC50 of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a KB of 0.18 nM for Gq dissociation) at the 5-HT2A receptor. 2-Bromo-LSD D-Tartrate exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT2A. 2-Bromo-LSD D-Tartrate lacks 5-HT2B agonist activity. 2-Bromo-LSD D-Tartrate induces dendritogenesis and spinogenesis. 2-Bromo-LSD D-Tartrate reverses the behavioral effects of chronic stress and increases active coping behaviors in mice.
DC80035 2-Bromo-5-Chloroterephthalic Acid 2-Bromo-5-Chloroterephthalic Acid (2-Bromo-5-chloroterephthalic acid) is a metal-organic framework (MOF).
DC80011 1-Nonadecanoin-2,3-acetyl 1-Nonadecanoin-2,3-acetyl is an acylglycerol.
DC80001 1-Heptanoyl-2,3-diacetyl 1-Heptanoyl-2,3-diacetyl is an acylglycerol.
DC31079 Abarelix Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
X